Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07674654 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 114 to 113 Eligibility criteria expanded, about 48 wordsv5 Show 1 more changeShow less
    • Eligibility criteria expanded, about 48 words

    See this version in full on ClinicalTrials.gov ↗

  2. Site details revised at 30 of 114 sitesv4
  3. Recruitment opened Study sites: 115 to 114 · Start date changed from estimate of Jul 2026 to Aug 3, 2026v3 Show 2 more changesShow less
    • Study sites: 115 to 114
    • Start date changed from estimate of Jul 2026 to Aug 3, 2026
  4. Trial sites reduced: 120 → 115 locationsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kallyope Inc.
4 trials monitored
See all monitored trials
Migraine
467 trials monitored
See 24 trials at risk
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
Trial Details
NCT Number NCT07674654
Lead Sponsor Kallyope Inc.
Conditions Acute Migraine
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov